Literature DB >> 18538298

Vision-related quality of life in patients with pituitary adenoma.

Yoshifumi Okamoto1, Fumiki Okamoto, Takahiro Hiraoka, Shozo Yamada, Tetsuro Oshika.   

Abstract

PURPOSE: To evaluate the vision-related quality of life (VR-QOL) in patients with pituitary adenoma.
DESIGN: Prospective, consecutive, comparative case series.
METHODS: A VR-QOL questionnaire was distributed to 154 patients with pituitary adenoma and 81 normal controls. These were presurgical patients. VR-QOL was measured using the 25-Item National Eye Institute Visual Function Questionnaire (VFQ-25). The influence of various factors on VFQ-25 score was assessed, including age, logarithm of the minimum angle of resolution best-corrected visual acuity (logMAR BCVA), critical flicker fusion frequency, Humphrey static perimetry scores, and the duration of ocular symptoms.
RESULTS: The VFQ-25 composite score was significantly lower in patients with pituitary adenoma than in the normal controls (P < .001), with significant differences in all subscales except for color vision. The VFQ-25 composite score in patients with pituitary adenoma was significantly correlated with logMAR BCVA, mean deviation (MD) and corrected pattern standard deviation (CPSD) of Humphrey perimetry, critical flicker fusion frequency, and the duration of ocular symptoms. Stepwise multiple regression analysis revealed that MD score in the better-seeing eye (r = 0.69; P < .001) and the duration of ocular symptoms associated with pituitary adenoma (r = -0.36; P < .001) were significantly related to the VFQ-25 composite score.
CONCLUSIONS: The VR-QOL is significantly deteriorated in patients with pituitary adenoma. The degree of visual field defect in the better-seeing eye and duration of ocular symptoms were found to be significantly related to the decline of VR-QOL in these patients.

Entities:  

Mesh:

Year:  2008        PMID: 18538298     DOI: 10.1016/j.ajo.2008.04.018

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  7 in total

1.  Quantitative and functional visual field outcomes after endoscopic trans-sphenoidal pituitary adenectomy.

Authors:  Dhruv Parikh; James M W Robins; Tess Garretty; Asim J Sheikh; Atul K Tyagi; Paul A Nix; Nick I Phillips
Journal:  Acta Neurochir (Wien)       Date:  2022-04-15       Impact factor: 2.216

2.  Vision-related quality-of-life in pediatric primary brain tumor patients.

Authors:  Jason H Peragallo; Beau B Bruce; Caroline Vasseneix; Supharat Jariyakosol; Anna J Janss; Nancy J Newman; Valérie Biousse
Journal:  J Neurooncol       Date:  2021-08-30       Impact factor: 4.506

3.  Vision specific quality of life in children with optic pathway gliomas.

Authors:  Robert A Avery; Kristina K Hardy
Journal:  J Neurooncol       Date:  2013-11-07       Impact factor: 4.130

4.  A novel Bayesian adaptive method for mapping the visual field.

Authors:  Pengjing Xu; Luis Andres Lesmes; Deyue Yu; Zhong-Lin Lu
Journal:  J Vis       Date:  2019-12-02       Impact factor: 2.240

Review 5.  Visual fields in neuro-ophthalmology.

Authors:  Sachin Kedar; Deepta Ghate; James J Corbett
Journal:  Indian J Ophthalmol       Date:  2011 Mar-Apr       Impact factor: 1.848

Review 6.  Visual outcomes after endoscopic endonasal pituitary adenoma resection: a systematic review and meta-analysis.

Authors:  Ivo S Muskens; Amir H Zamanipoor Najafabadi; Vanessa Briceno; Nayan Lamba; Joeky T Senders; Wouter R van Furth; Marco J T Verstegen; Timothy R S Smith; Rania A Mekary; Christine A E Eenhorst; Marike L D Broekman
Journal:  Pituitary       Date:  2017-10       Impact factor: 4.107

7.  Low vision status and declining vision decrease Health-Related Quality of Life: Results from a nationwide 11-year follow-up study.

Authors:  Joonas Taipale; Alexandra Mikhailova; Matti Ojamo; Janika Nättinen; Saku Väätäinen; Mika Gissler; Seppo Koskinen; Harri Rissanen; Päivi Sainio; Hannu Uusitalo
Journal:  Qual Life Res       Date:  2019-08-10       Impact factor: 4.147

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.